This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Jane Huang Biography and Net Worth

CMO of BeiGene

Jane Huang, M.D., joined our Company in September 2016 as our Chief Medical Officer, Hematology. Prior to joining us, Dr. Huang served as the Vice President, Clinical Development at Acerta Pharma from 2015 to 2016, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Previously, she worked at Genentech from 2005 to 2015, serving most recently as Group Medical Director, where she played a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab. She is also an Adjunct Clinical Assistant Professor in Oncology at Stanford University, specializing in Thoracic Oncology. Dr. Huang received her Bachelor of Science degree in Biological Sciences from Stanford University and her M.D. from University of Washington School of Medicine. She is board certified in hematology, oncology, and internal medicine, and she completed her residency in Internal Medicine and fellowships in Hematology and Oncology at Stanford University.

What is Jane Huang's net worth?: The estimated net worth of Jane Huang is at least $4.27 million as of April 6th, 2023. Dr. Huang owns 24,220 shares of BeiGene stock worth more than $4,274,830 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Huang may own. Learn More about Jane Huang's net worth.
How do I contact Jane Huang?: The corporate mailing address for Dr. Huang and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Jane Huang's contact information.
Has Jane Huang been buying or selling shares of BeiGene?: Jane Huang has not been actively trading shares of BeiGene over the course of the past ninety days. Most recently, Jane Huang sold 1,500 shares of the business's stock in a transaction on Tuesday, December 14th. The shares were sold at an average price of $278.14, for a transaction totalling $417,210.00. Learn More on Jane Huang's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (Founder, Executive Chairman & CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 19 times. They sold a total of 1,214,613 shares worth more than $226,013,519.58. The most recent insider tranaction occured on December, 10th when insider Xiaodong Wang sold 41,760 shares worth more than $7,804,944.00. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 12/10/2024.

Jane Huang Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/14/2021	Sell	1,500	$278.14	$417,210.00
12/1/2021	Sell	1,049	$359.86	$377,493.14
11/17/2021	Sell	1,500	$381.34	$572,010.00
10/19/2021	Sell	1,500	$372.78	$559,170.00
9/20/2021	Sell	6,000	$397.96	$2,387,760.00
9/13/2021	Sell	12,901	$358.14	$4,620,364.14	145,235
9/1/2021	Sell	542	$310.53	$168,307.26	305,824
7/15/2021	Sell	21,000	$332.42	$6,980,820.00	298,661
6/7/2021	Sell	603	$351.55	$211,984.65	284,933
6/1/2021	Sell	540	$362.64	$195,825.60	292,772
5/28/2021	Sell	1,500	$356.30	$534,450.00	292,772
4/29/2021	Sell	1,500	$354.92	$532,380.00	285,583
3/29/2021	Sell	1,500	$324.00	$486,000.00	285,583
1/29/2021	Sell	1,500	$322.99	$484,485.00	285,583
12/29/2020	Sell	1,500	$249.13	$373,695.00	285,583
11/30/2020	Sell	1,500	$267.82	$401,730.00	285,583
10/29/2020	Sell	1,500	$300.06	$450,090.00	285,583
9/29/2020	Sell	1,500	$280.38	$420,570.00	285,583
9/3/2020	Sell	3,128	$233.07	$729,042.96	285,583
8/28/2020	Sell	3,000	$242.21	$726,630.00	326,247
7/29/2020	Sell	3,000	$209.93	$629,790.00	326,247
7/7/2020	Sell	3,921	$200.00	$784,200.00	326,247
6/29/2020	Sell	1,935	$190.83	$369,256.05	326,247
6/26/2020	Sell	2,079	$200.29	$416,402.91	326,247
6/8/2020	Sell	631	$170.84	$107,800.04	283,464
5/29/2020	Sell	1,500	$163.86	$245,790.00	291,667
4/29/2020	Sell	1,500	$162.30	$243,450.00	291,667
4/16/2020	Sell	1,500	$160.00	$240,000.00	291,667
1/21/2020	Sell	1,500	$170.69	$256,035.00	291,667
12/16/2019	Sell	1,500	$165.14	$247,710.00	291,667
11/18/2019	Sell	1,500	$194.49	$291,735.00	291,667
11/4/2019	Sell	32,900	$190.46	$6,266,134.00	291,667
9/3/2019	Sell	2,862	$144.45	$413,415.90	291,667
8/12/2019	Sell	2,500	$134.74	$336,850.00	328,873
7/29/2019	Sell	10,130	$134.54	$1,362,890.20	328,873
6/27/2019	Sell	430	$124.52	$53,543.60	3
5/20/2019	Sell	300	$130.12	$39,036.00	271,621
4/8/2019	Sell	14,130	$142.77	$2,017,340.10	271,621
3/11/2019	Sell	2,636	$130.28	$343,418.08	271,621
3/7/2019	Sell	71	$140.50	$9,975.50	271,621
11/26/2018	Sell	3,000	$139.58	$418,740.00	271,621
9/4/2018	Sell	2,911	$174.60	$508,260.60
12/21/2017	Sell	1,000	$98.00	$98,000.00	1,000
12/13/2017	Sell	1,500	$94.25	$141,375.00	1,500
12/4/2017	Sell	1,100	$86.00	$94,600.00	264,900
11/20/2017	Sell	1,600	$86.25	$138,000.00	264,900
11/16/2017	Sell	600	$85.00	$51,000.00	264,900

Jane Huang Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $176.50

$175.80

$179.25

50 Day Range

MA: $200.99

$174.72

$227.05

2 Week Range

Now: $176.50

$126.97

$248.16

Volume

337,011 shs

Average Volume

284,766 shs

Market Capitalization

$17.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

This Crypto Is Set to Explode in December

From Crypto 101 Media | Ad